title: Is the suppressive effect of cyproterone acetate on serum anti-Müllerian-hormone levels in women with polycystic ovary syndrome stronger than under oral contraceptive pill?
abstract: OBJECTIVE
  To compare the suppressive effect of anti-androgen therapy by cyproterone acetate (CPA) and by oral contraceptive pill (OCP) on anti-müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) in order to detect a putative direct anti-androgen effect on AMH excess.
  
  
  METHODS
  This is a prospective longitudinal study including 58 women with PCOS between January 2010 and April 2014 at the Lille University Hospital. A total of 47 women with clinical hyperandrogenism were treated by CPA (50 mg/d was administered 20 days out of 28) and 11 women with PCOS but without clinical hyperandrogenism received OCP.
  
  
  RESULTS
  Serum AHM levels at baseline were similar in CPA and OCP groups (median [5-95th percentiles]: 60.4 pmol/l [25.1-200.2] versus 58 pmol/l [27.6-100], respectively, p = 0.39). After 3 months of treatment, serum AMH levels decreased significantly by 28% ± 20% and by 22% ± 27% in CPA and OCP groups, respectively. The decrease under both treatments was similar (p = 0.48).
  
  
  CONCLUSIONS
  That any anti-androgen effect could be observed on AMH in our CPA group in addition to the gonadotropin-suppressing effect suggests that either androgens are not involved in AMH regulation or that they act by interfering with gonadotropin effects on granulosa cells.
authors.affiliation: a Department of Endocrine Gynaecology and Reproductive Medicine , Hôpital Jeanne De Flandre , Lille , France and.
authors.forename: Pauline
authors.initials: P
authors.lastname: Plouvier
authors.affiliation: a Department of Endocrine Gynaecology and Reproductive Medicine , Hôpital Jeanne De Flandre , Lille , France and.
authors.forename: Maëliss
authors.initials: M
authors.lastname: Peigné
authors.affiliation: b Department of Reproductive Medicine , Hôpital Jean Verdier , Bondy , France.
authors.forename: Héloïse
authors.initials: H
authors.lastname: Gronier
authors.affiliation: a Department of Endocrine Gynaecology and Reproductive Medicine , Hôpital Jeanne De Flandre , Lille , France and.
authors.forename: Geoffroy
authors.initials: G
authors.lastname: Robin
authors.affiliation: a Department of Endocrine Gynaecology and Reproductive Medicine , Hôpital Jeanne De Flandre , Lille , France and.
authors.forename: Sophie
authors.initials: S
authors.lastname: Catteau-Jonard
authors.affiliation: a Department of Endocrine Gynaecology and Reproductive Medicine , Hôpital Jeanne De Flandre , Lille , France and.
authors.forename: Didier
authors.initials: D
authors.lastname: Dewailly
mesh_terms: D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D054304:Anti-Mullerian Hormone / Q000097:blood*; D003276:Contraceptives, Oral / Q000008:administration & dosage / Q000494:pharmacology*; D017373:Cyproterone Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood* / Q000188:drug therapy*; D008137:Longitudinal Studies; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000726:Androgen Antagonists; D003276:Contraceptives, Oral; D017373:Cyproterone Acetate; D054304:Anti-Mullerian Hormone
keywords: Anti-androgen therapy; anti-müllerian hormone; cyproterone acetate; oral contraceptive pill; polycystic ovary syndrome